Arthrosamid

Arthrosamid is a long‑acting injectable hydrogel (polyacrylamide, 97.5% water + 2.5% cross‑linked polymer) used to treat knee osteoarthritis by cushioning the joint, reducing pain, and improving function after a single injection. It integrates into the synovial lining to provide durable relief, with studies showing benefits lasting 2–5 years.

Arthrosamid is

  • A non‑biodegradable hydrogel implant injected into the knee joint.

  • Composition: 97.5% water + 2.5% cross‑linked polyacrylamide.

  • Designed to thicken and reinforce the synovial lining, improving lubrication and reducing mechanical stress.

Arthrosamid acts through a mechanical and structural mechanism, not a biochemical one:

  • Distributes through the synovial cavity and bonds with synovial tissue.

  • Creates a permanent cushioning layer that reduces joint friction.

  • Leads to long‑lasting pain reduction and improved mobility.

  • Unlike hyaluronic acid, it does not degrade, giving it a much longer duration of effect

Arthrosamid is intended for:

  • Adults with mild to moderate knee osteoarthritis

  • Patients who have not responded to:

    • Physiotherapy

    • NSAIDs

    • PRP

    • Hyaluronic acid injections

  • Those wanting to delay or avoid knee replacement surgery

Significant pain reduction lasting at least 3 years.

Some studies report benefits up to 5 years post‑treatment.

Considertions

  • Mild swelling or discomfort after injection is common.

  • Infection risk is low but present—patients receive prophylactic antibiotics before the procedure.

  • Not a cure for OA, but a long‑acting symptomatic treatment.

  • Availability in Australia currently requires TGA special access approval